Analyst Downgrades Weigh on Nokia Shares Despite AI Breakthrough

Nokia shares fell after two downgrades to 'Hold,' overshadowing a new medical AI innovation from Bell Labs. Profit-taking and US network challenges also pressured the stock.

Nokia's stock faced notable selling pressure following a pair of analyst downgrades, even as the company's research division announced a significant advancement in medical artificial intelligence. Shares declined approximately 3.6% in the session.

Dual Downgrades Dampen Sentiment

Market sentiment was impacted by two separate recommendation cuts issued on the same day. Analysts at Danske Bank and DNB Carnegie both reduced their ratings on Nokia from "Buy" to "Hold." The two European institutions set a price target of €6.50 per share.

This cautious stance from some analysts contrasts with a more bullish view held elsewhere. Morgan Stanley reaffirmed its "Overweight" recommendation on the equity and raised its price objective to €8.50, presenting a substantially more optimistic valuation than its European counterparts.

Underlying Pressures Beyond Ratings

Market observers note that concerns extend beyond the immediate analyst actions. Specific apprehension surrounds Nokia's business in the United States, where a major mobile carrier is embarking on a multi-year project to replace legacy radio technology. This demanding undertaking is expected to consume considerable resources and is tempering near-term expectations.

Furthermore, the pullback appears partially driven by profit-taking. Following weeks of optimism focused on AI and network-related themes, investors are locking in gains. Nokia's equity had enjoyed a strong run, still holding a gain of roughly 23% since the start of the year. Viewed in that context, the recent retreat appears less severe.

Bell Labs Unveils Healthcare AI Innovation

Amid the market discussion, Nokia Bell Labs, in collaboration with biomedical engineers from Duke University, published pioneering research in the journal Cell Biomaterials. The work centers on an AI-powered optical coherence tomography system designed to non-invasively analyze wound healing processes.

The study demonstrated that a hydrogel with greater mechanical stiffness—assessed using this novel imaging technique—significantly enhances tissue regeneration and vascularization. This project highlights how Nokia is leveraging its AI expertise beyond telecommunications, applying it to specialized healthcare applications. The potential for this to evolve into a meaningful business segment will depend on successful future commercialization efforts.

Investor Focus Shifts to Execution

In the near term, investor attention is likely to remain fixed on Nokia's financial trajectory and strategic plans. The company recently provided its outlook for 2026 and detailed ongoing restructuring initiatives. With 2025 revenue reported at €22.5 billion, the market is now assessing the credibility of the growth path for the current fiscal year.